Search Results - "KONOPLEVA, M" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

by DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., Glytsou, C., Fleming, S.A., Zhang, Q., Ma, H., Patel, K.P., Kornblau, S.M., Xu, Z., Chua, C.C., Chen, Xufeng, Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D.C.S, Roberts, A.W., Majewski, I.J., Konopleva, M., Wei, A.H.
Published in Blood (12.03.2020)

Get full text

Journal Article

Integration of hypoxic HIF-α signaling in blood cancers

Integration of hypoxic HIF-α signaling in blood cancers

by Schito, L, Rey, S, Konopleva, M
Published in Oncogene (21.09.2017)

Get full text

Journal Article

Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

by Konopleva, M., Milella, M., Ruvolo, P., Watts, J. C., Ricciardi, M. R., Korchin, B., Teresa, McQueen, Bornmann, William, Tsao, T., Bergamo, P., Mak, D. H., Chen, W., McCubrey, J., Tafuri, A., Andreeff, M.
Published in Leukemia (01.09.2024)

Get full text

Journal Article

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

by Boddu, P, Jorgensen, J, Kantarjian, H, Borthakur, G, Kadia, T, Daver, N, Alvarado, Y, Pemmaraju, N, Bose, P, Naqvi, K, Yilmaz, M, Pierce, S, Brandt, M, DiNardo, C D, Jabbour, E J, Konopleva, M, Garcia-Manero, G, Cortes, J, Ravandi, F
Published in Leukemia (01.01.2018)

Get full text

Journal Article

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

by Zhang, W, Konopleva, M, Ruvolo, V R, McQueen, T, Evans, R L, Bornmann, W G, McCubrey, J, Cortes, J, Andreeff, M
Published in Leukemia (01.04.2008)

Get full text

Journal Article

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

by Daver, N, Kantarjian, H, Ravandi, F, Estey, E, Wang, X, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Verstovsek, S, Kadia, T, Dinardo, C, Pierce, S, Huang, X, Pemmaraju, N, Diaz-Pines-Mateo, M, Cortes, J, Borthakur, G
Published in Leukemia (01.02.2016)

Get full text

Journal Article

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

by Zhou, L, Ruvolo, V R, McQueen, T, Chen, W, Samudio, I J, Conneely, O, Konopleva, M, Andreeff, M
Published in Leukemia (01.06.2013)

Get full text

Journal Article

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn CXCR4 interactions in lipid rafts

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn CXCR4 interactions in lipid rafts

by Tabe, Y, Jin, L, Iwabuchi, K, Wang, R-Y, Ichikawa, N, Miida, T, Cortes, J, Andreeff, M, Konopleva, M
Published in Leukemia (01.05.2012)

Get full text

Journal Article

The dual PI3 kinase mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

The dual PI3 kinase mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

by Kojima, K, Shimanuki, M, Shikami, M, Samudio, I J, Ruvolo, V, Corn, P, Hanaoka, N, Konopleva, M, Andreeff, M, Nakakuma, H
Published in Leukemia (01.09.2008)

Get full text

Journal Article

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

by KONOPLEVA, M, MILELLA, M, MAK, D. H, CHEN, W, MCCUBREY, J, TAFURI, A, ANDREEFF, M, RUVOLO, P, WATTS, J. C, RICCIARDI, M. R, KORCHIN, B, MCQUEEN, T, BORNMANN, W, TSAO, T, BERGAMO, P
Published in Leukemia (01.04.2012)

Get full text

Journal Article

Influence of IDH on FLT3-ITD status in newly diagnosed AML

Influence of IDH on FLT3-ITD status in newly diagnosed AML

by Boddu, P, Takahashi, K, Pemmaraju, N, Daver, N, Benton, C B, Pierce, S, Konopleva, M, Ravandi, F, Cortes, J, Kantarjian, H, DiNardo, C D
Published in Leukemia (01.11.2017)

Get full text

Journal Article

Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins

Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins

by Konopleva, M, Konoplev, S, Hu, W, Zaritskey, A Y, Afanasiev, B V, Andreeff, M
Published in Leukemia (01.09.2002)

Get full text

Journal Article

Apoptosis effector mechanisms: a requiem performed in different keys

Apoptosis effector mechanisms: a requiem performed in different keys

by Hail, Jr, N, Carter, B Z, Konopleva, M, Andreeff, M
Published in Apoptosis (London) (01.06.2006)

Get full text

Journal Article

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

by Ravandi, F, Arana Yi, C, Cortes, J E, Levis, M, Faderl, S, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Estrov, Z, Borthakur, G, Thomas, D, Pierce, S, Brandt, M, Pratz, K, Luthra, R, Andreeff, M, Kantarjian, H
Published in Leukemia (01.07.2014)

Get full text

Journal Article

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

by Jain, P, Kantarjian, H, Ravandi, F, Thomas, D, O'Brien, S, Kadia, T, Burger, J, Borthakur, G, Daver, N, Jabbour, E, Konopleva, M, Cortes, J, Pemmaraju, N, Kelly, M A, Cardenas-Turanzas, M, Garris, R, Faderl, S
Published in Leukemia (01.04.2014)

Get full text

Journal Article

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML

by Shastri, A., Chakraborty, S., Morganti, C., Zhang, H., Rivera-Pena, B., Ito, K., Konopleva, M.
Published in Leukemia research reports (2024)

Get full text

Journal Article

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

by Montalban-Bravo, G, Huang, X, Jabbour, E, Borthakur, G, DiNardo, C D, Pemmaraju, N, Cortes, J, Verstovsek, S, Kadia, T, Daver, N, Wierda, W, Alvarado, Y, Konopleva, M, Ravandi, F, Estrov, Z, Jain, N, Alfonso, A, Brandt, M, Sneed, T, Chen, H-C, Yang, H, Bueso-Ramos, C, Pierce, S, Estey, E, Bohannan, Z, Kantarjian, H M, Garcia-Manero, G
Published in Leukemia (01.02.2017)

Get full text

Journal Article

$Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia$

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

by RICCIARDI, M. R, MCQUEEN, T, CHISM, D, MILELLA, M, ESTEY, E, KALDJIAN, E, SEBOLT-LEOPOLD, J, KONOPLEVA, M, ANDREEFF, M
Published in Leukemia (01.09.2005)

Get full text

Journal Article

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

by Ruvolo, P P, Qui, Y H, Coombes, K R, Zhang, N, Ruvolo, V R, Borthakur, G, Konopleva, M, Andreeff, M, Kornblau, S M
Published in Leukemia (01.11.2011)

Get full text

Journal Article

$A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia$

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

by Uy, G L, Rettig, M P, Stone, R M, Konopleva, M Y, Andreeff, M, McFarland, K, Shannon, W, Fletcher, T R, Reineck, T, Eades, W, Stockerl-Goldstein, K, Abboud, C N, Jacoby, M A, Westervelt, P, DiPersio, J F
Published in Blood cancer journal (New York) (10.03.2017)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
Next
[10]